The private network has gone months without new batches from Qdenga, but recently received a “safety supply”
The dengue vaccine produced by pharmaceutical company Takeda has been offered again in some private clinics in the country. The factories have gone months without new batches of Qdenga due to the priority of the vaccination campaign in the Unified Health System (SUS), but the supply to the private network has been resumed.
According to the company, “a safety stock has been made available to meet the demand of the population not eligible for the vaccine through the Unified Health System (SUS), and also to guarantee the second dose for people who have already received the vaccine before on the private network.”
Takeda also informs that the quantity of doses offered to the private network, at this time, “remains low due to the priority given to satisfying the demand for SUS”.
On the websites of laboratories and pharmacy chains, one dose can be found at prices ranging from R$ 360 to R$ 420. Since the vaccination program requires two doses three months apart, the package costs R$ 720 to R$ 840.
Who can get the vaccine?
Due to the limited production capacity of the vaccine, the Ministry of Health has decided that only children aged 10 to 14, living in the 1,920 pre-selected municipalities, can take Qdenga in public units. At the time of the announcement, the ministry explained that the choice was linked to the higher rate of hospitalization for illness among patients of this age.
The vaccine, however, is approved by the National Health Surveillance Agency (Anvisa) for a wider audience: it can be administered to people aged 4 to 60.
Exceptions in this age group include people allergic to vaccine components; immunosuppressed people, such as people with HIV or undergoing chemotherapy; pregnant and breastfeeding women.
Is the dengue vaccine still offered in the public health system?
YES. Municipalities like San Paolo have had to deal with the lack of vaccinebut they also received a lot again. The capital, for example, received 124,216 new doses of Qdenga last Thursday 11 and will send the shipment exclusively to children and adolescents who have already taken the first dose and are ready for the second.
The vaccine is available in the Basic Health Units for request from Monday to Friday. On Saturdays, immunization is carried out only in the Integrated AMA/UBS. To find the station closest to your home, go to “Health Research” Platform..
Historical epidemic
The vaccine is tetravalent, that is, it stimulates the production of antibodies against the four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3 and DENV-4), registered simultaneously in the country in 2024.
According to the ministry, all states have shown circulation of types 1 and 2. Roraima, Pará, Amapá, Maranhão, Piauí, Paraíba, Pernambuco, Alagoas, Bahia, Minas Gerais, Rio de Janeiro, São Paulo, Paraná, Santa Catarina and Mato Grosso do Sul have circulation of serotypes 1, 2 and 3, and there have been sporadic detections of DENV-4 in Goiás, Mato Grosso do Sul and Minas Gerais.
Concomitant circulation is one of the factors identified for the historic epidemic recorded this year in the country. Anomalies in temperature and precipitation trends are also among the causes of the explosion in cases, according to the latest epidemiological bulletin published by the government.
As of the end of June, 6,215,201 probable cases of dengue have been reported in the country, an increase of 344.5% compared to the same period in 2023. 82,908 cases of dengue with warning signs and severe dengue have been confirmed, an increase of 307.8% compared to last year, and 4,269 people have died from the disease. Another 2,737 reported deaths remain under investigation.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
